Author ' s response to reviews Title : Lenalidomide in heavily pretreated refractory diffuse large B - cell lymphoma
نویسندگان
چکیده
Title:Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma Thank you for the reviewers' comments on our manuscript, now titled " Lenalidomide in Heavily Pretreated Refractory Diffuse Large B-cell Lymphoma: A Case Report. " We are pleased that the reviewers would consider this manuscript for publication in Journal of Medical Case Reports after satisfactory revision. The manuscript has been revised to address all of the reviewers' comments, and a point-by-point response to these suggestions is attached. My coauthors and I believe that these changes have improved the manuscript, and the thoughtful reviews are appreciated. Please direct all correspondence to my attention or contact me by telephone at +48 602 338290 or by e-mail at [email protected] with any questions. I look forward to hearing from you. Response to Comment #1: Per your request, " a case report " was added to the end of the previous title and now reads " Lenalidomide in Heavily Pretreated Refractory Diffuse Large B-cell Lymphoma: A Case Report. " Editorial Comment #2: Please include the ethnicity of the patient in the abstract and case presentation sections. Response to Comment #2: We agree that the ethnicity of the patient is important and have included this information in the abstract (page 2, under " Case Presentation ") and Case Presentation (page 5, first paragraph) sections of the manuscript. Editorial Comment #3: Please include the patient's gender (male/female). Response to Comment #3: We agree that the patient's gender is an important piece of information and have added this information to the abstract (page 2, under " Case Presentation ") and Case Presentation (page 5, first paragraph) sections of the manuscript. Editorial Comment #4: Please change the " Background " section header to " Introduction ". Response to Comment #4: As requested, the " Background " section header was changed to " Introduction " and can be found on page 3 of the manuscript. Editorial Comment #5: Please do not include sub-headings in the " Case Presentation " section. Response to Comment #5: All sub-headings were removed from the " Case Presentation " section of the manuscript. Editorial Comment #6: Please remove dates of confinement in the " Case Presentation " section. Response to Comment #6: As requested and to help maintain the anonymity of the patient, the specific years he received treatment were removed from the text (pages 5-9), appropriate figures (Figure 2 and Figure 4) and figure legends …
منابع مشابه
Lenalidomide in heavily pretreated refractory diffuse large B-cell lymphoma: a case report
INTRODUCTION In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not candidates for autologous stem cell therapy. Options ...
متن کاملA comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Lenalidomide is an oral non-chemotherapy immunomodulator with direct and indirect effects on non-Hodgkin lymphoma (NHL) cells and with single-agent activity in relapsed/refractory aggressive and indolent B-cell NHL, including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma, and follicular lymphoma. Based on the pivotal phase II MCL-001 trial of lenalidomide in heavily pretreated patie...
متن کاملBCL2 Family Related Genes Expression and Chemotherapy Response in Diffuse Large B-Cell Lymphoma
Background and Objective: Approximately half of patients with diffuse large B-cell lymphoma are cured with current chemotherapy regimens. The purpose of this study was to evaluate Bax and Bcl2 expression and their relationship with the response to chemotherapy. Materials and Methods This study was a prospective analysis on 44 patients with diffuse large B-cell lymphoma. Their specimens we...
متن کاملLong-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study
BACKGROUND Mantle cell lymphoma (MCL) is an uncommon type of non-Hodgkin lymphoma with poor overall prognosis, requiring the development of new therapies. Lenalidomide is an immunomodulatory agent demonstrating antitumor and antiproliferative effects in MCL. We report results from a long-term subset analysis of 57 patients with relapsed/refractory MCL from the NHL-003 phase II multicenter study...
متن کاملmiR-4284 and miR-4484 as Putative Biomarkers for Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma is the most common type of non-Hodgkin lymphoma. MicroRNAs (miRNAs) are endogenous small RNA, which can regulate gene expression at the post-transcriptional level. MiRNA profiling has shown a great potential as novel diagnostic and prognostic biomarkers. The present study was performed at the Nemazee Teaching Hospital (Shiraz, Iran) from 2011 to 2013.The aim of thi...
متن کامل